Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REBAT

Financiado

Cerrado

Redox homeostasis in BRCA1 associated tumorigenesis

"Mutations of BRCA1 tumor suppressor gene account for 5-10% of hereditary breast cancers. Clinically, BRCA1-mutated cancers represent a unique subtype, with distinctive risk factors and poor prognosis. High-throughput technologies... ver más

Fecha desconocida

INSTITUT CATALA D'...

230K€

Presupuesto del proyecto: 230K€

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSTITUT CATALA D'ONCOLOGIA

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BRCANCER A novel approach for modeling development of breast cancer 208K€ Cerrado

SAF2010-20493 IMPLICACIONES DEL TIPO DE MUTACION GERMINAL EN EL PRONOSTICO... 97K€ Cerrado

SAF2014-57680-R PROFUNDIZANDO EN EL MECANISMO DE ACCION DE LOS INHIBIDORES D... 97K€ Cerrado

CNS2023-145149 Cáncer 200K€ Cerrado

BRCA-ERC Understanding cancer development in BRCA 1 2 mutation carrie... 2M€ Cerrado

SAF2010-21165 ANALISIS GENOMICO DEL CANCER FAMILIAR MEDIANTE SECUENCIACION... 97K€ Cerrado

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Presupuesto del proyecto 230K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Mutations of BRCA1 tumor suppressor gene account for 5-10% of hereditary breast cancers. Clinically, BRCA1-mutated cancers represent a unique subtype, with distinctive risk factors and poor prognosis. High-throughput technologies have identified genomic and transcriptomic signatures that are shared by sporadic and BRCA1-mutated breast tumors. BRCA1 mutations have been implicated in other types of tumors such as gastric, pancreatic and prostate cancers. A more detailed picture of BRCA1 tumor suppression functions is needed to design better tailored therapies for these aggressive cancers. BRCA1-mutated tumors tend to accumulate mutations in PTEN and p53 tumor suppressor genes. The current model of BRCA1-related tumorigenesis posits that in BRCA1 mutation carries, the cell of origin bearing BRCA1 mutation at heterozygote status, undergoes loss of BRCA1 wild-type allele and loss or mutation of PTEN and p53 tumor suppressors. Although this intriguing model lacks in vivo evidence, it is widely accepted that PTEN and p53 gene inactivation are required for survival and transformation of BRCA1-mutated cells. BRCA1, PTEN and p53 have been implicated in the regulation of intracellular levels of reactive oxygen species (ROS). Redox homeostasis derives from an imbalance between ROS generation and elimination. Redox homeostasis is crucial in the maintenance of cellular functions and it has implications in tumor development and sensitivity to anti-cancer therapies. This study will investigate the role of PTEN and p53-regulated pathways in affecting the redox homeostasis of BRCA1 null cells. The activity of Nrf2 and FoxO transcription factors that regulate ROS and are related to BRCA1, PTEN and p53 will be considered. These signalling pathways will be analyzed in normal mouse mammary gland and in human breast cancers. Results will be translated into pre-clinical settings through orthoxenografts of primary human tumor samples and in vivo administration of chemotherapeutics."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores